MRNA Overview
Upcoming Projects (MRNA)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (MRNA)
-
A third look: Discussion of CMV and potential of CMV vaccine MRNA-1647
Ticker: MRNA
Executed On: Aug 21, 2024 at 03:45 PM EDT -
A second look: Discussion of CMV and potential of CMV vaccine MRNA-1647
Ticker: MRNA
Executed On: Aug 15, 2024 at 09:30 AM EDT -
Discussion of CMV and potential of CMV vaccine MRNA-1647
Ticker: MRNA
Executed On: Aug 13, 2024 at 04:30 PM EDT -
Discussing the potential of CAR-M technology, including CAR-Macrophages and CAR-Monocytes, for immunotherapies aimed at solid tumors and specifically an in vivo CAR-M targeting Glypican-3 (GPC3).
Tickers: CARM, MRNA
Executed On: Jul 09, 2024 at 03:45 PM EDT -
A Third View: Looking into Moderna's recently approved mRESVIA (mRNA-1345), an mRNA vaccine for protecting against RSV infection.
Ticker: MRNA
Executed On: Jul 02, 2024 at 06:30 PM EDT -
A Second View: Looking into Moderna's recently approved mRESVIA (mRNA-1345), an mRNA vaccine for protecting against RSV infection.
Ticker: MRNA
Executed On: Jun 28, 2024 at 09:30 AM EDT -
A Third Opinion: Delving into the phase 3 clinical trial data on Moderna's combination Covid-19 and Flu vaccine mRNA-1083 in patients 50 years and older.
Ticker: MRNA
Executed On: Jun 21, 2024 at 02:00 PM EDT -
Looking into Moderna's recently approved mRESVIA (mRNA-1345), an mRNA vaccine for protecting against RSV infection.
Ticker: MRNA
Executed On: Jun 21, 2024 at 10:30 AM EDT -
A Second Opinion: Delving into the phase 3 clinical trial data on Moderna's combination Covid-19 and Flu vaccine mRNA-1083 in patients 50 years and older.
Ticker: MRNA
Executed On: Jun 20, 2024 at 03:00 PM EDT -
Delving into the phase 3 clinical trial data on Moderna's combination Covid-19 and Flu vaccine mRNA-1083 in patients 50 years and older.
Ticker: MRNA
Executed On: Jun 18, 2024 at 01:00 PM EDT -
A Third Opinion: Discussing the potential of the Moderna's combination vaccine candidate for Covid-19 and Influenza, mRNA-1083
Ticker: MRNA
Executed On: Oct 13, 2023 at 10:00 AM EDT -
A Second Opinion: Discussing the potential of the Moderna's combination vaccine candidate for Covid-19 and Influenza, mRNA-1083
Ticker: MRNA
Executed On: Oct 13, 2023 at 09:00 AM EDT -
Discussing the potential of the Moderna's combination vaccine candidate for Covid-19 and Influenza, mRNA-1083
Ticker: MRNA
Executed On: Oct 12, 2023 at 04:15 PM EDT -
A Third Opinion: Discussing the standard of care and the potential of the two updated Covid-19 booster shots from Pfizer/BioNTech and Moderna for this fall season
Tickers: PFE, MRNA
Executed On: Oct 03, 2023 at 04:00 PM EDT -
A Second Opinion: Discussing the standard of care and the potential of the two updated Covid-19 booster shots from Pfizer/BioNTech and Moderna for this fall season
Tickers: PFE, MRNA
Executed On: Sep 28, 2023 at 01:35 PM EDT -
Discussing the standard of care and the potential of the two updated Covid-19 booster shots from Pfizer/BioNTech and Moderna for this fall season.
Tickers: PFE, MRNA
Executed On: Sep 20, 2023 at 12:00 PM EDT -
A second look: Discussing the potential of mRNA-4157, a personalized mRNA-based cancer vaccine, in combination with the immune checkpoint inhibitor, pembrolizumab, for patients with high-risk melanoma
Tickers: MRNA, MRK
Executed On: May 04, 2023 at 06:00 PM EDT -
Discussing the potential of mRNA-4157, a personalized mRNA-based cancer vaccine, in combination with the immune checkpoint inhibitor, pembrolizumab, for patients with high-risk melanoma
Tickers: MRK, MRNA
Executed On: May 03, 2023 at 10:00 AM EDT -
A third discussion of the new covid vaccines targeting omicron variant, with a focused look at the potential of Ocugen's first in class nasal vaccine
Tickers: OCGN, PFE, MRNA, JNJ
Executed On: Nov 09, 2022 at 11:00 AM EST -
A second discussion of the new covid vaccines targeting omicron variant, with a focused look at the potential of Ocugen's first in class nasal vaccine
Tickers: OCGN, PFE, MRNA, JNJ
Executed On: Oct 27, 2022 at 11:30 AM EDT -
Discussing the new covid vaccines targeting omicron variant, with a focused look at the potential of Ocugen's first in class nasal vaccine
Tickers: OCGN, PFE, MRNA
Executed On: Oct 17, 2022 at 02:00 PM EDT -
Discussing the safety and efficacy of the new covid vaccines targeting omicron variant
Tickers: MRNA, AZN, PFE
Executed On: Sep 09, 2022 at 05:30 PM EDT
Upcoming & Overdue Catalysts (MRNA)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (MRNA)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
